AbbVie Inc. (ABBV) · Oct 5, 2026 · Guidance
Guidance cut — Q3 EPS midpoint $3.75 vs. prior $3.86; FY midpoint $13.86 vs. prior $13.97
AbbVie cuts 2026 EPS guidance after a $216M acquired R&D and milestone charge; the hit looks transactional but lands below Q3 consensus.
AbbVie is navigating the post-Humira transition by using fast-growing Skyrizi and Rinvoq to replace lost legacy revenue while expanding its immunology pipeline through deals such as Apogee. Skyrizi and Rinvoq were still growing roughly 24% year over year in the latest reported quarter, while Humira revenue was falling sharply.
The immediate change is a clean guidance cut, not a demand warning. AbbVie expects a $216 million pre-tax acquired in-process research and development and milestone expense in the third quarter, reducing adjusted EPS by $0.11. The Q3 adjusted EPS range falls from $3.84-$3.88 to $3.73-$3.77, while full-year guidance drops from $13.87-$14.07 to $13.76-$13.96 (Guidance table).
| Period | Previous guidance | New guidance | Change in midpoint |
|---|---|---|---|
| Q3 2026 adjusted EPS | $3.84-$3.88 | $3.73-$3.77 | -$0.11 |
| FY 2026 adjusted EPS | $13.87-$14.07 | $13.76-$13.96 | -$0.11 |
| Acquired IPR&D and milestones expense | — | $216 million | -$0.11 EPS impact |
The result is below the near-term earnings bar. The new Q3 range midpoint of $3.75 is about $0.11 below the published consensus near $3.86, so this is worse than what analysts were expecting even though the charge is tied to pipeline investment rather than weaker product sales.
The underlying business story is largely unchanged, but earnings visibility is less clean. AbbVie says these acquired R&D and milestone costs cannot be reliably forecast beyond the third quarter, leaving room for further one-off adjustments if more deals or licensing milestones occur. 〔0〕
Bottom line: This is a modest earnings setback caused by another pipeline-related charge, not evidence in this filing of weakening core drug demand. It still lowers the near-term profit outlook below expectations and adds uncertainty around future business-development spending.
Q3 earnings report, October 30
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.